anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The following information should be provided to patients receiving ENDODAN tablets by their physician, nurse, pharmacist, or caregiver:

  1. Patients should be aware that ENDODAN tablets contain oxycodone, which is a morphine-like substance. 
  2. Patients should be instructed to keep ENDODAN tablets in a secure place out of the reach of children. In the case of accidental ingestions, emergency medical care should be sought immediately. 
  3. When ENDODAN tablets are no longer needed, the unused tablets should be destroyed by flushing down the toilet. 
  4. Patients should be advised not to adjust the medication dose themselves. Instead, they must consult with their prescribing physician. 
  5. Patients should be advised that ENDODAN tablets may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g., driving, operating heavy machinery). 
  6. Patients should not combine ENDODAN tablets with alcohol, opioid analgesics, tranquilizers, sedatives, or other CNS depressants unless under the recommendation and guidance of a physician. When co-administered with another CNS depressant, ENDODAN tablets can cause dangerous additive central nervous system or respiratory depression, which can result in serious injury or death. 
  7. The safe use of ENDODAN tablets during pregnancy has not been established; thus, women who are planning to become pregnant or are pregnant should consult with their physician before taking ENDODAN tablets. 
  8. Nursing mothers should consult with their physicians about whether to discontinue nursing or discontinue ENDODAN tablets because of the potential for serious adverse reactions to nursing infants. 
  9. Patients who are treated with ENDODAN tablets for more than a few weeks should be advised not to abruptly discontinue the medication. Patients should consult with their physician for a gradual discontinuation dose schedule to taper off the medication. 
  10. Patients should be advised that ENDODAN tablets are a potential drug of abuse. They should protect it from theft, and it should never be given to anyone other than the individual for whom it was prescribed. 
  11. Patients should be advised that ENDODAN tablets may cause or worsen constipation. They should discuss any past history of constipation with their prescribing physician so a management plan may be initiated.
PURPOSE:A sugar-coated tablet of multiple vitamin, containing a magnesium ingredient as a mineral ingredient essential to prevention of diseases in circulatory systems in a sugar coating layer and hardly causing a change of various vitamins with time. CONSTITUTION:A sugar-coated tablet of multiple vitamins produced by tableting an uncoated tablet prepared by blending, e.g. various vitamins, e.g. vitamins A, B, C, D, E, etc., using a normally used tablet machine. The resultant uncoated tablet is then subjected to sugar coating with a kneading solution obtained by previously blending a magnesium ingredient and a sprinkling agent to give the aimed sugar-coated tablet. Thereby a large amount of the Mg ingredient having very strong drug interaction can be blended and the tablet is very stable even in such a case and hardly causing deterioration in quality of the various vitamins.
PURPOSE:To provide a microcapsule preparation which has both sustained activity and slow-releasability of the drug component and can be guided with magnetic field, by coating a drug component with an organic polymer containing ferromagnetic particles. CONSTITUTION:Particles of drug component coated with an organic polymer and firmly attached with ferromagnetic particles, are obtained by (1) dissolving an organic polymer (e.g. ethylcellulose, gelatin, albumin, etc.) and optionally an adjuvant in an organic solvent, (2) adding the drug component and ferromagnetic powders (e.g. ferrite powder, Pt-Co powder, iron powder, etc.) to the hot solution thus obtained, and (3) stirring and slowly cooling the mixture. The coated particles are washed with a solution of a surface active agent (e.g. HCO-60, Tween 80, etc.) to obtain the objective product. When administered in the body, the particles can be guided directly to the diseased part with the outer magnetic field, thereby exhibiting the maximum remedying effect with little side effects.
The use of a peptide fraction (A), isolated from organs of high reticuloendothelial system (RES) content, for treating metabolic disorders associated with weight loss is new. (A) is produced by enzymatic proteolysis of organs rich in RES, then gel-chromatographic isolation of the active fraction (see DE 3827490). USE/ADVANTAGE - (A) increases appetite and wt. gain in patients with cancer, AIDS or severe infections. It significantly improves the quality of life and improves side effects caused by anticancer treatments. (A) is free of side effects.
FIELD: medicine, medicinal immunology. SUBSTANCE: invention relates to the field of preparing highly purified and highly active protein preparations of the immune system of body that can be used in medicine and biochemistry for development of test-systems and for research aims. Method involves precipitation of blood serum euglobulins by dialysis against distilled water followed by dialysis of dissolved precipitate of euglobulin fraction against solution at pH 8.6-9.0 containing 1 mM of ε-aminocaproic acid and 0.01 M of EDTA. After removal of precipitated impurities supernatant is saturated with Na 2 SO 4 , formed precipitate is dissolved in solution at pH 6 containing 11% of Na 2 SO 4 , 0.005 M of Na 2 HPO 4  and 0.01 M of EDTA and C3 component of complement is precipitated from the formed solution by dialysis against distilled water. Method provides preparing the complement of C3 component at the yield 60%. Obtained preparation has a single precipitation band with antiserum to all human serum proteins and has no impurities by immunoelectrophoresis and electrophoresis in polyacrylamide gel data. EFFECT: simplified method, high purity of preparation, absence of impurities, increased yield. 1 ex
Inflammation has a pronounced impact on the intestinal ecosystem by driving an expansion of facultative anaerobic bacteria at the cost of obligate anaerobic microbiota. This pathogen "blooming" is also a hallmark of enteric Salmonella enterica serovar Typhimurium (S. Tm) infection. Here, we analyzed the contribution of bacterial and host factors to S. Tm "blooming" in a gnotobiotic mouse model for S. Tm-induced enterocolitis. Mice colonized with the Oligo-Mouse-Microbiota (OMM12), a minimal bacterial community, develop fulminant colitis by day 4 after oral infection with wild-type S. Tm but not with an avirulent mutant. Inflammation leads to a pronounced reduction in overall intestinal bacterial loads, distinct microbial community shifts, and pathogen blooming (relative abundance >50%). S. Tm mutants attenuated in inducing gut inflammation generally elicit less pronounced microbiota shifts and reduction in total bacterial loads. In contrast, S. Tm mutants in nitrate respiration, salmochelin production, and ethanolamine utilization induced strong inflammation and S. Tm "blooming." Therefore, individual Salmonella-specific inflammation-fitness factors seem to be of minor importance for competition against this minimal microbiota in the inflamed gut. Finally, we show that antibody-mediated neutrophil depletion normalized gut microbiota loads but not intestinal inflammation or microbiota shifts. This suggests that neutrophils equally reduce pathogen and commensal bacterial loads in the inflamed gut.
PURPOSE:To predict the concentration of a gradually releasable granule in blood plasma inside a living body without being affected by the release control mechanism of the gradually releasable granule by a method wherein, after the gradually releasable granule has been treated with oils and fats, it is stirred and eluted at the specific number of revolutions together with beads and the elution amount of a medicine at intervals of a prescribed time is measured. CONSTITUTION:A gradually releasable granule is treated with oils and fats; after that, it is stirred and eluted at 15 to 100 revolutions per minute together with Teflon beads 2; the elution amount of a medicine at intervals of a prescribed time is measured. The gradually releasable granule represents a granule preparation and a powder preparation which have been made gradually releasable or whose release has been controlled; it may be provided with any release control mechanism. A vehicle which is used to control the elution is not limited especially; a water-soluble polymer, a water- nonsoluble polymer and the like are combined; they are mixed with a main medicine such as acetaminophen or the like or they are used as an elution control film. Oils and fats which are a liquid at room temperature are used as the oils and fats; a medium-chain fatty acid triglycerine such as, e.g. Panasate, Coconad or the like or vegetable oil such as soybean oil, cottonseed oil or the like is used.
Pre- and Post-Liver Transplantation Patients

Additional adverse reactions observed from an open-label study (Study 435) in pre- and post- liver transplantation patients with chronic hepatitis B and lamivudine-resistant hepatitis B administered Adefovir Dipivoxil Tablets once daily for up to 203 weeks include: abnormal renal function, renal failure, vomiting, rash, and pruritus. 

Changes in renal function occurred in pre-and post-liver transplantation patients with risk factors for renal dysfunction, including concomitant use of cyclosporine and tacrolimus, renal insufficiency at baseline, hypertension, diabetes, and on-study transplantation. Therefore, the contributory role of Adefovir Dipivoxil Tablets to these changes in renal function is difficult to assess. 

Increases in serum creatinine greater than or equal to 0.3 mg/dL from baseline were observed in 37% and 53% of pre-liver transplantation patients by Weeks 48 and 96, respectively, by Kaplan-Meier estimates. Increases in serum creatinine greater than or equal to 0.3 mg/dL from baseline were observed in 32% and 51% of post-liver transplantation patients by Weeks 48 and 96, respectively, by Kaplan-Meier estimates. Serum phosphorus values less than 2 mg/dL were observed in 3/226 (1.3%) of pre-liver transplantation patients and in 6/241 (2.5%) of post-liver transplantation patients by last study visit. Four percent (19 of 467) of patients discontinued treatment with Adefovir Dipivoxil Tablets due to renal adverse events.
A system for determining a set of characteristics of a participant performing an activity is provided. The system includes two or more data collectors and a processor. The two or more data collectors include a physical data collector for collecting physical data associated with the activity and a physiological data collector for collecting physiological data associated with the activity. The processor has one or more data inputs in communication with the processor. Each of the one or more data inputs communicates with at least one of the data collectors to receive the physical data or the physiological data. The processor is adapted to receive the physical data and the physiological data from the one or more data inputs and process the physical data and the physiological data according to a characteristic generation program. The set of characteristics represents a performance level of the participant performing the physical activity.
Subjects will receive a brief intervention on smoking reduction with a warning message plus a smoking reduction leaflet. They will be asked to think about a tailored smoking reduction schedule for themselves after the negotiation with the trained counsellor. The trained counsellor will negotiate a schedule with subjects to reduce their smoking over an acceptable level. For the subsequent telephone follow up in the intervention group, information on reduction and cessation will be collected, followed by a "booster" intervention, which will repeat the health warning to positively encourage them to reinforce their efforts and the next reduction target. Four consecutive (1, 3, 6 and 12 months) follow-ups will be conducted over the telephone by trained interviewers.
<P>PROBLEM TO BE SOLVED: To provide a manufacturing method of a vesicle by which a high encapsulating ratio of a desired substance can be attained while controlling desired physical properties such as particle size.  <P>SOLUTION: W/O emulsion is produced by blending an oil phase containing an emulsifier with an aqueous solution containing the substance to be encapsulated in a dissolved state or a suspended state. Then the W/O emulsion is cooled to temperature at which the aqueous solution therein becomes frozen particles while the oil phase maintains a liquid state and the oil phase is removed. Then the oil phase containing a vesicle constituting lipid is added to the frozen particles and obtained mixture is agitated to substitute the vesicle constituting lipid for the emulsifier at a frozen particle surface. Further an outside aqueous phase is added to the frozen particle the surface of which is covered with a lipid membrane to hydrate the outside aqueous phase and the lipid membrane.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a non-steroidal anti-inflammatory drug may cause a dose dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate over renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, patients with volume depletion, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. 

Increases in serum potassium concentration, including hyperkalemia, have been reported with use of indomethacin, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state (see PRECAUTIONS: Drug Interactions). 

###  Advanced Renal Disease

No information is available from controlled clinical studies regarding the use of indomethacin in patients with advanced renal disease. Therefore, treatment with indomethacin is not recommended in these patients with advanced renal disease. If indomethacin therapy must be initiated, close monitoring of the patient's renal function is advisable.
Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, their derivatives and analogues are known as inhibitors of HMG-CoA reductase and are used as antihypercholesterolemics. Most of them are produced by fermentation with microorganisms of various kinds belonging to genera Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium, while some of them are the result of treatment of fermentation products with methods of chemical synthesis or the result of a total chemical synthesis. The purity of the active substance is an important factor of production of a safe and effective medicament, especially when the latter is to be taken for a long period, as in the case of healing or prevention of a high cholesterol level in blood. The accumulation of impurities from lower purity medicaments may produce several side effects during the therapy. The submitted invention refers to a new industrial process of isolation of inhibitors of HMG-CoA reductase by means of a so-called displacement chromatography. The application of the invention enables the production of high-purity inhibitors of HMG-CoA reductase at a high yield, as low costs as possible, and a favourable ecological balance.
The purpose of the current study is to offer a preliminary test of feasibility and acceptability for a group intervention, conducted in a primary care setting, that aims to teach skills that initiate health behavior change. Participants will be recruited from a local family medicine clinic and groups will be held on site at the clinic. Patients will be recruited by their physicians and given a baseline survey of their exercise and nutrition behaviors as well as their overall well being and self efficacy to change their health behaviors. Participants can join the group at any time and attend as many sessions as desired. Groups are held 2 times per month and include worksheets, meditations, and exercise. Patients and their providers will be given 2 follow up surveys after 5 and 13 weeks to assess for acceptability and feasibility of the program, as well as health behavior change. Statistical analyses will include multivariate analyses, descriptive analyses, and frequency data collection.
CD19 is frequently targeted for immunotherapy in B cell malignancies, which may result in loss of CD19 expression in leukemic cells as an escape mechanism. Stage 0 hematogones (Hgs) are normal CD19-negative very early B cell precursors that can be potentially mistaken for CD19 negative residual leukemic cells by flow cytometry (FCM) in B cell acute lymphoblastic leukemia (BCP-ALL) cases treated with anti CD19 therapy. Our main objective was to characterize and study the incidence of stage 0 hematogones in follow-up bone marrow samples of pediatric BCP-ALL cases. We analyzed the flow cytometry standard files of 61 pediatric BCP-ALL cases treated with conventional chemotherapy and targeted anti-CD19 therapy, for identifying the residual disease and normal B cell precursors including stage 0 Hgs. A non-CD19 alternate gating strategy was used to isolate the B cells for detecting the residual disease and stage 0 Hgs. The stage 0 Hgs were seen in 95% of marrow samples containing CD19+ Hgs. When compared with controls and posttransplant marrow samples, the fraction of stage 0 Hgs was higher in patients receiving anti CD19 therapy (p = 0.0048), but it was not significant when compared with patients receiving chemotherapy (p = 0.1788). Isolated stage 0 Hgs are found in samples treated with anti-CD19 therapy simulating CD19 negative residual illness. Our findings aid in understanding the stage 0 Hgs and its association with CD19+ Hgs in anti CD19 therapy and conventional chemotherapy. This is crucial as it can be potentially mistaken for residual disease in patients treated with anti CD19 therapy.
PURPOSE:To activate the lymphocytes in the blood of a cancer patient and to intensify an anti-tumor effect by bringing the blood into contact with a carrier having the higher affinity to the granulocytes than the lymphocytes to lower the ratio of the number of the granulocytes to the number of the lymphocytes in the blood and adding cytokinin to the blood. CONSTITUTION:This method consists in bringing the blood into contact with the carrier having the higher affinity to the granulocytes than the lymphocytes to lower the ratio of the number of the granulocytes to the number of the lymphocytes (G/L ratio) in the blood and adding the cytokinin to the blood. Any materials are usable as the carrier, insofar as these materials are not detrimental to the blood which comes into contact with this carrier; more preferably the carrier having 55 to 95 deg. contact angle with water is used. More specifically, polystyrene, cellulose acetate, nylon, such as 6-nylon and 11-nylon, polytrifluoroethylene, and polyethylene terephthalate, are particularly adequate. The cytokinin is exemplified by IL-1alpha considered to have the anti-tumor activity, IL-4 considered to have an effect of propagating T cells, IL-5 considered to have an effect of propagating sell segmentation, etc., in addition to IL-2, etc.
A randomised controlled trial will be conducted to determine the effectiveness of a programme "Coaching Ongoing Momentum Building On stroKe rEcovery journeY" ("COMBO-KEY"), a home visiting and phone coaching programme, on community-dwelling stroke survivors' self-efficacy, outcome expectation, and engagement in stroke self-management behaviours. An estimated sample of 134 stroke survivors will be recruited. COMBO-KEY will be underpinned by Bandura's constructs of self-efficacy and outcome expectation. It will be delivered by trained coaches. Outcomes will be measured at baseline and immediately after completion of the programme. Generalised estimating equations model will be used to assess the differential changes in outcome variables from pre-test to post-test between the intervention and control groups with adjustment for their baseline levels.
The implications of sleep as it relates to the physiology and pathogenesis of a number of diseases has until recently been ignored. With the evolution of sleep laboratories, there is an emerging recognition of the relationship between sleep and various gastrointestinal diseases in particular gastroesophageal reflux disease (GERD). Twenty five (25) patients meeting entry criteria will be compared with 25 matching historical control patients who do not have GERD symptoms or sleep disturbance. Patients will record heartburn symptoms and GERD-associated sleep disturbances on a diary card. These patients will be evaluated for baseline functionality GERD symptom scores, PSQI, driving simulator, bed partner questionnaire (optional) and receive 40 mg daily of Nexium® for 4 weeks. Primary outcome variable driving simulator performance will be the relief of nighttime heartburn during the last 7 days of the trial as recorded by the patient on a diary card. Secondary outcome variables include change from baseline to week 4 in the PSQI score, percentage of patients with complete resolution of sleep disturbances, relief of sleep disturbances, and percentage of days without GERD-associated sleep disturbances. Assessment of patients with complete resolution of daytime, night times, and 24-hour heartburn symptoms, and the percentage of patients with relief of daytime and 24-hour heartburn symptoms. The driving simulator performance will be compared at baseline and after 4 weeks of therapy with Nexium®. Also, where available, the bed partner PSQI will be compared at baseline and following treatment of the primary patient with Nexium® for 4 weeks.